The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 08, 2016
Filed:
Feb. 22, 2015
Applicant:
Aerpio Therapeutics Inc., Cincinnati, OH (US);
Inventors:
Robert Shalwitz, Bexley, OH (US);
Joseph H. Gardner, Cincinnati, OH (US);
Assignee:
AERPIO THERAPEUTICS, INC., Cincinnati, OH (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4412 (2006.01); C07D 211/96 (2006.01); A61K 31/44 (2006.01); A61K 31/4439 (2006.01); A61K 31/4545 (2006.01); A61K 31/496 (2006.01); A61K 31/501 (2006.01); A61K 31/5377 (2006.01); A61K 31/541 (2006.01); A61K 31/55 (2006.01); C07D 213/02 (2006.01); C07D 213/69 (2006.01); C07D 401/06 (2006.01); C07D 401/14 (2006.01); C07D 417/06 (2006.01); C07D 491/113 (2006.01); A61K 31/4427 (2006.01); A61K 31/444 (2006.01); A61K 45/06 (2006.01); C07D 211/86 (2006.01);
U.S. Cl.
CPC ...
C07D 211/96 (2013.01); A61K 31/44 (2013.01); A61K 31/444 (2013.01); A61K 31/4412 (2013.01); A61K 31/4427 (2013.01); A61K 31/4439 (2013.01); A61K 31/4545 (2013.01); A61K 31/496 (2013.01); A61K 31/501 (2013.01); A61K 31/5377 (2013.01); A61K 31/541 (2013.01); A61K 31/55 (2013.01); A61K 45/06 (2013.01); C07D 211/86 (2013.01); C07D 213/02 (2013.01); C07D 213/69 (2013.01); C07D 401/06 (2013.01); C07D 401/14 (2013.01); C07D 417/06 (2013.01); C07D 491/113 (2013.01);
Abstract
Disclosed herein are methods for controlling the activity of hypoxia-inducible transcription factor 1-alpha (HIF-1α) and diseases, conditions, or syndromes related thereto, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia. Further disclosed are pharmaceutical compositions comprising HIF-1α prolyl hydroxylase inhibitors useful in treating diseases, conditions, and/or syndromes related thereto the activity of HIF-1α.